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Genetic Disorders of Renal Phosphate Transport
To the Editor: In their comprehensive review of 
genetic disorders of renal phosphate transport, 
Prié and Friedlander (June 24 issue)1 claim that 
the role of NPT2a in renal phosphate handling 
has been shown by the association between het-
erozygous mutations in NPT2a and renal phos-
phate leak.2 However, Virkki et al.3 found no 
dominant negative effect of these NPT2a variants, 
which indicates that they are polymorphisms. 
Lapointe et al.4 also identified NPT2a variants in 
patients with renal phosphate leak, but ruled out 
their functional significance by the finding of 
normal renal phosphate balance in family mem-
bers carrying the same variants. The major con-
tribution of NPT2a to renal phosphate balance 
was definitively established in a recent article in 
the Journal that reported autosomal recessive 
 hypophosphatemic rickets with renal Fanconi’s 
syndrome secondary to a loss-of-function muta-
tion in SLC34A1 (also known as NPT2a), the gene 
that encodes NPT2a (also known as NaPi-IIa).5
Daniella Magen, M.D. 
Israel Zelikovic, M.D. 
Karl Skorecki, M.D.
Rambam Health Care Campus 
Haifa, Israel 
danmag@tx.technion.ac.il
No potential conflict of interest relevant to this letter was re-
ported.
1. Prié D, Friedlander G. Genetic disorders of renal phosphate 
transport. N Engl J Med 2010;362:2399-409.
2. Prié D, Huart V, Bakouh N, et al. Nephrolithiasis and osteo-
porosis associated with hypophosphatemia caused by mutations 
in the type 2a sodium-phosphate cotransporter. N Engl J Med 
2002;347:983-91.
3. Virkki LV, Forster IC, Hernando N, Biber J, Murer H. Func-
tional characterization of two naturally occurring mutations in 
the human sodium-phosphate cotransporter type IIa. J Bone 
Miner Res 2003;18:2135-41.
4. Lapointe JY, Tessier J, Paquette Y, et al. NPT2a gene variation 
in calcium nephrolithiasis with renal phosphate leak. Kidney Int 
2006;69:2261-7.
5. Magen D, Berger L, Coady MJ, et al. A loss-of-function muta-
tion in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med 
2010;362:1102-9.
To the Editor: The review by Prié and Fried-
lander discusses hypophosphatemia with neph-
rolithiasis and bone demineralization due to 
heterozygous mutations in NPT2a.1 We observed 
hypophosphatemia in a boy with the Sotos syn-
drome due to a heterozygous microdeletion on 
5q35, which removed the NSD1 and NPT2a genes. 
The cause of the Sotos syndrome, which is man-
ifested by macrocephaly, bone overgrowth with 
advanced bone age, and mental retardation,2 is 
haploinsufficiency of the NSD1 gene.3 The index 
patient presented with severe hypophosphatemia 
in the neonatal period (serum phosphorus level, 
0.4 to 0.9 mg per deciliter; normal range, 4.8 to 
8.2), which persisted but was less pronounced 
during later years (3.7±0.6 mg per deciliter). The 
maximum tubular reabsorption of phosphate nor-
malized for the glomerular filtration rate mea-
sured at the age of 4 years was 3.4 mg per deciliter 
(reference range for age, 4.6±0.6). Serum levels of 
calcium and parathyroid hormone remained in 
the normal range, but 1,25-dihydroxyvitamin D3 
levels were slightly elevated. Nephrocalcinosis, 
rickets, and osteoporosis were not present. Five 
other patients with the Sotos syndrome who had 
mutations that did not affect NPT2a had normo-
phosphatemia. Our observation broadens the 
clinical spectrum of the Sotos syndrome and in-
dicates that a haploinsufficiency of NPT2a is suf-
ficient to cause hypophosphatemia.
Elena Levtchenko, M.D., Ph.D.
University Hospitals Leuven  
Leuven, Belgium  
elena.levtchenko@uzleuven.be
Joost Schoeber, Ph.D. 
Jacques Jaeken, M.D., Ph.D.
University of Leuven  
Leuven, Belgium
No potential conflict of interest relevant to this letter was re-
ported.
1. Prié D, Huart V, Bakouh N, et al. Nephrolithiasis and osteo-
porosis associated with hypophosphatemia caused by mutations 
in the type 2a sodium-phosphate cotransporter. N Engl J Med 
2002;347:983-91.
2. Sotos JF, Dodge PR, Muihead D, Crawford JD, Talbot ND. 
Cerebral gigantism in childhood: a syndrome of excessive rapid 
growth and acromegalic features and a nonprogressive neuro-
logic disorder. N Engl J Med 1964;271:109-16.
3. Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficien-
cy of NSD1 causes Sotos syndrome. Nat Genet 2002;30:365-6.
The authors reply: Magen et al. reported on 
two relatives with a Fanconi’s syndrome, renal 
insufficiency, and a homozygous mutation in 
SLC34A1, which encodes NPT2a.1 This phenotype 
was more complex than that of patients with het-
erozygous NPT2a mutations.2 It is surprising that 
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the decrease in NPT2a expression alone could 
explain the whole phenotype. These unexpected 
features might result from intracellular accumu-
lation of this particular mutant protein and there-
by in a toxic effect on renal cells. This property 
is not necessarily shared with other NPT2a mu-
tants. In these highly consanguineous patients, 
additional mutations in genes other than NPT2a 
could also participate. This important paper was 
published while our review article was at an ad-
vanced stage of the publication process, thereby 
preventing us from discussing it.
We previously reported the association be-
tween heterozygous NPT2a mutations and renal 
phosphate loss.2 These mutations decreased phos-
phate transport; the coexpression of wild-type 
and mutated NPT2a proteins in oocytes resulted 
in phosphate transport that was lower than ex-
pected, a result that we interpreted as a dominant 
negative effect of mutant NPT2a. Virkki et al. 
confirmed that the mutations we had identified 
markedly decreased NPT2a activity.3 These au-
thors did not, however, detect a dominant nega-
tive effect of the NPT2a mutants by introducing 
a cysteine residue in NPT2a, under the assump-
tion that this modification would reveal an inter-
action between wild-type and mutant NPT2a. 
However, the validity of an interaction between 
wild-type and mutant NPT2a is unknown.
Lapointe et al. found no association between 
hypophosphatemia and a previously unidentified 
variant of NPT2a.4 No definitive conclusion can 
be drawn, however, regarding the consequences 
of other mutations.
The data reported by Levtchenko et al. suggest 
that NPT2a haploinsufficiency can induce hypo-
phosphatemia, an observation consistent with the 
defect of renal phosphate transport seen in pa-
tients with NPT2a heterozygous mutations.
As detailed in our most recent review, muta-
tions in genes other than NPT2a may lead to 
decreased NPT2a expression and thus to renal 
phosphate loss and hypophosphatemia. This en-
lightens the central role of NPT2a in phosphate 
homeostasis.
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Acupuncture for Chronic Low Back Pain
To the Editor: In their review article, Berman et 
al. (July 29 issue)1 discuss the use of acupuncture 
for chronic low back pain. Acupuncture, which 
originated in China, has been practiced there 
and in other Asian countries for thousands of 
years. The selection of acupuncture points and 
manual manipulation are performed according 
to the diagnosis and as determined by the theo-
ries of traditional Chinese medicine. However, 
when acupuncture is studied by practitioners of 
conventional medicine, insertion points are se-
lected from lists of commonly used points on the 
basis of the diagnosis as determined by conven-
tional medicine.2-6
In traditional Chinese medicine, the diagno-
sis, which is based on inquiry, inspection, olfac-
tion, auscultation, percussion, palpation, and 
pulse examination, guides point selection and 
manual manipulation for every acupuncture point 
in each treatment session. The lack of a correct 
diagnosis on this basis could explain the reported 
result that real acupuncture was no more effec-
tive than sham acupuncture in the clinical trials 
that were cited by Berman et al.
The diagnostic assessments of both conven-
tional and traditional Chinese medicine are re-
quired for tailored acupuncture treatment. Further 
studies to evaluate the efficacy of acupuncture 
should incorporate the diagnosis according to 
traditional Chinese medicine.
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